Telix Pharmaceuticals Limited
TLPPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $593 | $594 | $189 | $282 |
| % Growth | -0.2% | 214.5% | -32.9% | – |
| Cost of Goods Sold | $305 | $208 | $65 | $58 |
| Gross Profit | $288 | $386 | $124 | $224 |
| % Margin | 48.6% | 64.9% | 65.6% | 79.5% |
| R&D Expenses | $124 | $75 | $46 | $98 |
| G&A Expenses | $73 | $64 | $59 | $44 |
| SG&A Expenses | $147 | $112 | $64 | $106 |
| Sales & Mktg Exp. | $74 | $48 | $0 | $26 |
| Other Operating Expenses | $2 | $130 | $0 | $0 |
| Operating Expenses | $273 | $317 | $110 | $204 |
| Operating Income | $16 | $68 | $14 | $20 |
| % Margin | 2.7% | 11.5% | 7.3% | 7.1% |
| Other Income/Exp. Net | -$23 | -$21 | -$5 | -$5 |
| Pre-Tax Income | -$7 | $47 | $9 | $15 |
| Tax Expense | $4 | $9 | -$3 | -$4 |
| Net Income | -$3 | $38 | $12 | $20 |
| % Margin | -0.6% | 6.4% | 6.2% | 6.9% |
| EPS | -0.01 | 0.12 | 0.035 | 0.06 |
| % Growth | -108.6% | 243.8% | -42.1% | – |
| EPS Diluted | -0.01 | 0.11 | 0.033 | 0.06 |
| Weighted Avg Shares Out | 337 | 331 | 334 | 324 |
| Weighted Avg Shares Out Dil | 337 | 345 | 351 | 324 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $10 | $1 | $1 |
| Interest Expense | $4 | $17 | $5 | $1 |
| Depreciation & Amortization | $11 | -$2 | $4 | $2 |
| EBITDA | $9 | $77 | $40 | $23 |
| % Margin | 1.5% | 12.9% | 21.3% | 8.2% |